Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.07 (-8.12%)
Close on Nov 12, 2026Market cap $285.72MP/E –Yield 0.00%
Allogene Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Allogene Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$179.05M. For fiscal 2025 it was -$196.96M. The highest annual figure on record is -$169.69M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$196.96M | – |
| FY2024 | Dec 31, 2024 | -$259.56M | – |
| FY2023 | Dec 31, 2023 | -$313.54M | – |
| FY2022 | Dec 31, 2022 | -$321.24M | – |
| FY2021 | Dec 31, 2021 | -$169.69M | – |
| FY2020 | Dec 31, 2020 | -$250.84M | – |
| FY2019 | Dec 31, 2019 | -$197.41M | – |
| FY2018 | Dec 31, 2018 | -$191.84M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$52.21M | – |
| Q2 FY2026 | Jun 30, 2026 | -$44.28M | – |
| Q1 FY2026 | Mar 31, 2026 | -$43.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$39.35M | – |
| Q3 FY2025 | Sep 30, 2025 | -$41.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$53.71M | – |
| Q1 FY2025 | Mar 31, 2025 | -$62.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$57.26M | – |
| Q3 FY2024 | Sep 30, 2024 | -$68.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$67.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$65.95M | – |
| Q4 FY2023 | Dec 31, 2023 | -$81.63M | – |
| Q3 FY2023 | Sep 30, 2023 | -$59.42M | – |
| Q4 FY2019 | Dec 31, 2019 | -$62.70M | – |
| Q3 FY2019 | Sep 30, 2019 | -$53.83M | – |
| Q2 FY2019 | Jun 30, 2019 | -$44.96M | – |
| Q1 FY2019 | Mar 31, 2019 | -$35.92M | – |
| Q4 FY2018 | Dec 31, 2018 | -$32.70M | – |
| Q3 FY2018 | Sep 30, 2018 | -$21.84M | – |
| Q2 FY2018 | Jun 30, 2018 | -$134.71M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.60M | – |
See a number that looks wrong?